Evidence map›Paper›PMID 33231602›Full record

ArticleGenetics and molecular biology2020

Novel mutations in breast cancer patients from southwestern Colombia.

Melissa Solarte, Carolina Cortes-Urrea, Nelson Rivera Franco, Guillermo Barreto, Pedro A Moreno

Open access · goldAbstract read
In one paragraph

Article in Genetics and molecular biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Melissa SolarteUniversidad del Valle, School of Systems and Computing Engineering, Bioinformatics and Biocomputing Laboratory, Cali, Colombia.ORCID http://orcid.org/0000-0003-4754-7890
Carolina Cortes-UrreaUniversidad del Valle, School of Systems and Computing Engineering, Bioinformatics and Biocomputing Laboratory, Cali, Colombia.
Nelson Rivera FrancoUniversidad del Valle, Biology Department, Human molecular Genetic Laboratory, Cali, Colombia.
Guillermo BarretoUniversidad del Valle, Biology Department, Human molecular Genetic Laboratory, Cali, Colombia.ORCID http://orcid.org/0000-0003-2568-2629
Pedro A MorenoUniversidad del Valle, School of Systems and Computing Engineering, Bioinformatics and Biocomputing Laboratory, Cali, Colombia.
Universidad del Valle · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the leading cause of death by cancer among women in less developed regions. In Colombia, few published studies have applied next-generation sequencing technologies to evaluate the genetic factors related to breast cancer. This study characterized the exome of three patients with breast cancer from southwestern Colombia to identify likely pathogenic or disease-related DNA sequence variants in tumor cells. For this, the exomes of three tumor tissue samples from patients with breast cancer were sequenced. The bioinformatics analysis identified two pathogenic variants in Fgfr4 and Nf1 genes, which are highly relevant for this type of cancer. Specifically, variant FGFR4-c.1162G>A predisposes individuals to a significantly accelerated progression of this pathology, while NF1-c.1915C>T negatively alters the encoded protein and should be further investigated to clarify the role of this variant in this neoplasia. Moreover, 27 novel likely pathogenic variants were found and 10 genes showed alterations of pathological interest. These results suggest that the novel variants reported here should be further studied to elucidate their role in breast cancer.

Identifiers

PMID33231602
PMCPMC7684693
OpenAlexW3106548307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.